AGL 2263 – 5 mg

Brand:
Cayman
CAS:
638213-98-6
Storage:
-20
UN-No:
Non-Hazardous - /

AGL 2263 is an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R; IC50 = 0.43 μM).{25699} It also inhibits the insulin receptor (IR), protein kinase B (PKB), and Src in a cell-free assay (IC50s = 0.4, 55, and 2.2 μM, respectively). AGL 2263 inhibits IGF-1R autophosphorylation and phosphorylation of the downstream elements IRS-1, PKB, and ERK2 in an ATP-independent manner. It inhibits colony formation of PC3 and LNCaP prostate and MCF-7 and MDA-MB-468 breast cancer cells in soft agar (IC50s = 4.3, 9, 17, and 6 μM, respectively).  

 

Out of stock

SKU: 21776 - Category:

Description

An inhibitor of IGF-1R (IC50 = 0.43 μM); inhibits IR, PKB, and Src in a cell-free assay (IC50s = 0.4, 55, and 2.2 μM, respectively); inhibits IGF-1R autophosphorylation and phosphorylation of the downstream elements, IRS-1, PKB, and ERK2 in an ATP-independent manner; inhibits colony formation of PC3, LNCaP, MCF-7, and MDA-MB-468 cancer cells (IC50s = 4.3, 9, 17, and 6 μM, respectively),


Formal name: αE-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methylene]-3,4-dihydroxy-β-oxo-benzenepropanenitrile

Synonyms: 

Molecular weight: 322.3

CAS: 638213-98-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|IGF-1R/InsR Family||Product Type|Biochemicals|Kinase Inhibitors|SRC Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cancer|Cell Signaling|SRC Family Signaling